Complete loss of lineage defining antigens in two cases of B-cell malignancies following CAR-T therapy
Alireza Torabi, Jason E. Love, Teresa S. Hyun, Angie Pham et autres
us (code pays fourni par la source)
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
Alireza Torabi, Jason E. Love, Teresa S. Hyun, Angie Pham et autres
us (code pays fourni par la source)
Sally Arai, Joseph Pidala, Iskra Pusic, Xiaoyu Chai et autres
supplemental figure legend
Sally Arai, Joseph Pidala, Iskra Pusic, Xiaoyu Chai et autres
Supplemental Table. Grade 3-5 adverse events possibly, probably or definitely attributed to imatinib or rituximab Supplemental Figure 1. Vienna Skin Score (VSS) (1) Supplemental Figure 2. Photograph Range of Motion Scale - Modified from (2) Supplemental Figure 3. Total numbers of B …
Sally Arai, Joseph Pidala, Iskra Pusic, Xiaoyu Chai et autres
supplemental figure legend
Sally Arai, Joseph Pidala, Iskra Pusic, Xiaoyu Chai et autres
Abstract Purpose: Cutaneous sclerosis occurs in 20% of patients with chronic graft-versus-host disease (GVHD) and can compromise mobility and quality of life. Experimental design: We conducted a prospective, multicenter, randomized, two-arm phase II crossover trial of imatinib (200 mg daily) or rituximab …
Sally Arai, Joseph Pidala, Iskra Pusic, Xiaoyu Chai et autres
Abstract Purpose: Cutaneous sclerosis occurs in 20% of patients with chronic graft-versus-host disease (GVHD) and can compromise mobility and quality of life. Experimental design: We conducted a prospective, multicenter, randomized, two-arm phase II crossover trial of imatinib (200 mg daily) or rituximab …
Sally Arai, Joseph Pidala, Iskra Pusic, Xiaoyu Chai et autres
Supplemental Table. Grade 3-5 adverse events possibly, probably or definitely attributed to imatinib or rituximab Supplemental Figure 1. Vienna Skin Score (VSS) (1) Supplemental Figure 2. Photograph Range of Motion Scale - Modified from (2) Supplemental Figure 3. Total numbers of B …
Sarah V. Bradley, Mitchell Robert Smith, Teresa S. Hyun, Peter C. Lucas et autres
Abstract Huntingtin interacting protein 1 (HIP1) is an inositol lipid, clathrin, and actin binding protein that is overexpressed in a variety of epithelial malignancies. Here, we report for the first time that HIP1 is elevated in non–Hodgkin's and Hodgkin's lymphomas and that …
us (code pays fourni par la source)
Sarah V. Bradley, Eric C. Holland, Grace Y. Liu, Dafydd G. Thomas et autres
Abstract Huntingtin interacting protein 1 (HIP1) is a multidomain oncoprotein whose expression correlates with increased epidermal growth factor receptor (EGFR) levels in certain tumors. For example, HIP1-transformed fibroblasts and HIP1-positive breast cancers have elevated EGFR protein levels. The combined association of HIP1 …
us (code pays fourni par la source)
Sarah V. Bradley, Eric C. Holland, Grace Y. Liu, Dafydd G. Thomas et autres
Abstract Huntingtin interacting protein 1 (HIP1) is a multidomain oncoprotein whose expression correlates with increased epidermal growth factor receptor (EGFR) levels in certain tumors. For example, HIP1-transformed fibroblasts and HIP1-positive breast cancers have elevated EGFR protein levels. The combined association of HIP1 …
us (code pays fourni par la source)
Sarah V. Bradley, Eric C. Holland, Grace Y. Liu, Dafydd G. Thomas et autres
Supplementary Table 1 from Huntingtin Interacting Protein 1 Is a Novel Brain Tumor Marker that Associates with Epidermal Growth Factor Receptor
Sarah V. Bradley, Mitchell Robert Smith, Teresa S. Hyun, Peter C. Lucas et autres
Supplementary Figures 1-5, Tables 1-4 from Aberrant Huntingtin Interacting Protein 1 in Lymphoid Malignancies
BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.
L'essentiel de l'actu tech du Burkina & d'Afrique, chaque semaine dans votre boîte mail.
Gratuit · sans spam · désinscription en un clic